Washburn Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.01M Sell
842
-184
-18% -$188K 0.5% 31
2026
Q1
$945K Sell
1,026
-235
-19% -$238K 0.55% 29
2025
Q4
$1.35M Sell
1,261
-89
-7% -$85.1K 0.75% 23
2025
Q3
$1.03M Sell
1,350
-1,057
-44% -$787K 0.58% 29
2025
Q2
$1.88M Sell
2,407
-187
-7% -$145K 1.1% 16
2025
Q1
$2.14M Sell
2,594
-86
-3% -$71.6K 1.41% 14
2024
Q4
$2.07M Buy
2,680
+77
+3% +$63.8K 1.28% 14
2024
Q3
$2.31M Sell
2,603
-186
-7% -$167K 1.65% 13
2024
Q2
$2.53M Sell
2,789
-31
-1% -$24.8K 1.8% 12
2024
Q1
$2.19M Buy
2,820
+107
+4% +$76.1K 1.62% 12
2023
Q4
$1.58M Buy
2,713
+587
+28% +$343K 1.19% 14
2023
Q3
$1.14M Buy
2,126
+255
+14% +$131K 0.96% 20
2023
Q2
$877K Sell
1,871
-62
-3% -$26K 0.73% 22
2023
Q1
$664K Sell
1,933
-415
-18% -$140K 0.57% 29
2022
Q4
$859K Buy
2,348
+265
+13% +$94K 0.78% 24
2022
Q3
$674K Buy
2,083
+185
+10% +$58.6K 0.64% 26
2022
Q2
$615K Buy
+1,898
New +$570K 0.53% 30

Other funds holding LLY

Washburn Capital Management's LLY Position: Q2 2026 in Review

Washburn Capital Management reduced its Eli Lilly (LLY) stake by 18% in Q2 2026, selling an estimated $188K and leaving 842 shares worth $1.01M. The position accounts for 0.5% of the portfolio, ranked #31.

Washburn Capital Management first reported a position in LLY in Q2 2022 and has held it in 17 quarters since. The position peaked at $2.53M in Q2 2024. 1,692 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Washburn Capital Management held 842 shares of Eli Lilly worth $1.01M as of Q2 2026.
  • Washburn Capital Management sold 184 Eli Lilly shares in Q2 2026, an estimated $188K.
  • Eli Lilly made up 0.5% of Washburn Capital Management's portfolio in Q2 2026, its #31 holding.
  • Washburn Capital Management first reported a position in Eli Lilly in Q2 2022 and has held it in 17 quarters since.
  • Washburn Capital Management's Eli Lilly position peaked at $2.53M in Q2 2024.
  • 1,692 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Washburn Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.